Wolfgang Janni,
Head
Doctor Janni is currently full professor and director of the Department Obstetrics and Gynecology of the Heinrich-Heine-University Duesseldorf, Germany. He has been appointed to this position in October 2008, after working asdeputy director of the Department Obstetrics and Gynecology of the LMU University Munich. Doctor Janni has been appointed Junior Professor of the Department for Gynaecology and Obstetrics of the General Hospital of the Ludwig-Maximilians-University, Munich, in June 2003. Following several internships in major medical institutions, including the Yale University, the University of Michigan and New York University, Doctor Janni received his medical training at the LMU-University in Munich. He is board certified gynaecologist, with board certified subspecialities in gynaecological oncology and breast cancer, as well as perinatal medicine. Doctor Janni’s two main fields of research include the relevance of the detection of disseminated tumor cells in the bone marrow of breast cancer patients, and also clinical research. He developed the protocol for the ADEBAR-Study (A Randomized Phase III Trial Comparing FEC-Chemotherapy vs. EC-Doc-Chemotherapy in Patients with Primary Breast Cancer, n=1306 pts.), and was principal investigator of the SUCCESS-A-Trial, an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the disease free survival in patients treated with 3 cycles of FEC-chemotherapy, followed by 3 cycles of Docetaxel-chemotherapy versus 3 cycles of FEC, followed by 3 cycles of Gemcitabine-Docetaxel-chemotherapy, and to compare the disease free survival after randomisation in patients treated with 2 years of Zoledronate versus 5 years of Zoledronate in patients with early primary breast cancer (n=3.700 pts). He is currently conducting the Success C Trial, which is an open label, multicenter, 2x2 factorial design, randomized controlled, phase III study for early, HER2/neu-negative breast cancer patients. The first randomization of the study will compare the disease free survival in patients treated with 3 cycles of Epirubicin-Fluoruracil-Cyclophosphamide ( FEC ) -chemotherapy, followed by 3 cycles of Docetaxel ( D ) – chemotherapy versus 6 cycles of Docetaxel – Cyclophosphamide ( DC ) – chemotherapy. The second randomization will compare the disease free survival in patients with BMI of 24 – 40 kg / m² getting an individual lifestyle intervention versus not getting an individual lifestyle intervention. Women assigned to weight reduction arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention. Both trials comprise extensive translational research programs. His research received numerous international awards, including those of ASCO, AACR and SABCS. He is author and co-author of 125 publications in peer-reviewed journals, including the NEJM, JCO and CANCER, and is member of several editorial boards of reknown peer reviewed journals
|
|
